January 17, 2017 6:52 PM ET

Pharmaceuticals

Company Overview of Ritter Pharmaceuticals, Inc.

Company Overview

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. The company’s RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. Its RP-G28 has been studied in a Phase 2a clinical trial. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 20...

1880 Century Park East

Suite 1000

Los Angeles, CA 90067

United States

Founded in 2004

8 Employees

Phone:

310-203-1000

Fax:

310-919-1600

Key Executives for Ritter Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 56
Total Annual Compensation: $348.7K
Co-Founder, President and Director
Age: 33
Total Annual Compensation: $383.3K
Co-Founder, Executive Chairman and Chief Strategic Officer
Age: 66
Total Annual Compensation: $353.2K
Compensation as of Fiscal Year 2015.

Ritter Pharmaceuticals, Inc. Key Developments

Ritter Pharmaceuticals Announces Phase 2A Lactose Intolerance Clinical Trial Microbiome Data

Ritter Pharmaceuticals, Inc. announced that clinical microbiome data from its Phase 2a clinical trial of RP-G28 in patients with lactose intolerance were published in the Proceedings of the National Academy of Science ("PNAS-Plus") PNAS 2017; Early Edition, published ahead of print January 3, 2017. The paper titled, "Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals," reports findings on the Company's lead therapeutic candidate, RP-G28, a short-chain galactooligosaccharide ("GOS"). The data validates RP-G28's mechanism of action and supports the product as a potential treatment for lactose intolerance. The newly published microbiome data provides further insight into RP-G28's Phase 2a 2013 clinical trial, which has lead to a Phase 2b/3 377-subject clinical trial (results expected in 2017). The results of the study demonstrated that RP-G28 significantly modulated the gut microbiome composition of lactose intolerant individuals. Significant changes in the diversity of the microbiota occurred in GOS/RP-G28 treated subjects upon reintroduction of dairy into the diet. Key bacterial taxa changes included increases in lactose-fermenting Bifidobacterium, Lactobacillus and Faecalibacterium, and those changes correlated with a symptomatic improvement in tolerance to lactose (the sugar present in dairy foods). Notably, 90% of the RP-G28 treatment group showed a bifidogenic response compared to other GOS studies, which reported a bifidogenic response in 50% of the treated subjects.

Ritter Pharmaceuticals, Inc. Presents at LD Micro Main Event 2016, Dec-07-2016 11:00 AM

Ritter Pharmaceuticals, Inc. Presents at LD Micro Main Event 2016, Dec-07-2016 11:00 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States.

Ritter Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016

Ritter Pharmaceuticals, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported operating loss was $3,539,310 compared to $3,108,665 a year ago. Net loss was $3,526,071 compared to $3,080,222 a year ago. Net loss applicable to common shareholders was $3,526,071 or $0.41 per basic and diluted share compared to $3,080,222 or $0.40 per basic and diluted share a year ago. For the nine months, the company reported operating loss was $10,845,673 compared to $6,604,795 a year ago. Net loss was $10,793,993 compared to $6,564,956 a year ago. Net loss applicable to common shareholders was $10,793,993 or $1.26 per basic and diluted share compared to $6,955.808 or $2.35 per basic and diluted share a year ago.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ritter Pharmaceuticals, Inc., please visit www.ritterpharmaceuticals.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.